Nab-paclitaxel (Nab-P) in patients (pts) with HER2-ve advanced breast cancer (ABC): A focus on the elderly-Preliminary results of the GIM-13 AMBRA study.

被引：0

作者：

Mustacchi, Giorgio

Pronzato, Paolo

D'Alonzo, Alessia

Mocerino, Carmela

Romagnoli, Emanuela

Garrone, Ornella

Blasi, Livio

De Laurentiis, Michelino

Michelotti, Andrea

Bologna, Alessandra

Giordano, Monica

Turletti, Anna

Montemurro, Filippo

De Placido, Sabino

Natoli, Clara

Taverniti, Cristiana

Biganzoli, Laura

Meattini, Icro

Marchetti, Paolo

Cazzaniga, Marina Elena

机构：

[1] Univ Trieste, Trieste, Italy

[2] San Martino IST Ist Naz Ric Cancr, Genoa, Italy

[3] Osped Policlin San Martino Oncol Med, Genoa, Italy

[4] AORN A Cardarelli Hosp, Naples, Italy

[5] Osped Macerata, UOC Oncol, Macerata, Italy

[6] S Croce & Carle Teaching Hosp, Med Oncol, Cuneo, Italy

[7] Fdn San Raffaele Giglio, Palerio, Italy

[8] Fdn Pascale, Breast Unit, Naples, Italy

[9] Azienda Osped Univ Pisana, Oncol Unit 1, Pisa, Italy

[10] IRCCS Arcispedale Santa Maria Nuova, Reggio Emilia, Italy

[11] Santa Anna Hosp, Como, Italy

[12] ASLTO1 Osped Martini, Med Oncol, Turin, Italy

[13] Invest Clin Oncol Candiolo Canc Inst FPO IRCCS, Candiolo, Italy

[14] Univ Naples Federico II, Naples, Italy

[15] Univ G dAnnunzio, Dept Expt & Clin Sci, Chieti, Italy

[16] AOU Citta Salute & Sci, Med Oncol, Turin, Italy

[17] Hosp Prato, Sandro Pitigliani Med Oncol Dept, Prato, Italy

[18] Univ Florence, Florence, Italy

[19] Sapienza Univ Rome, S Andrea Hosp, Rome, Italy

[20] Hosp San Gerardo, Oncol Unit, Monza, MB, Italy

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.e13078

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e13078

引用

页数：1

共 50 条

[31] Analysis of prognostic factors in advanced pancreatic cancer (APDAC) patients (pts) undergoing to first-line nab-paclitaxel (Nab-P) and gemcitabine (G) treatment
Giordano, Guido
Vaccaro, Vanja
Lucchini, Eleonora
Bertocchi, Paola
Bergamo, Francesca
Musettini, Gianna
Santoni, Matteo
Lo Re, Giovanni
Giommoni, Elisa
Russano, Marco
Campidoglio, Serena
Santini, Daniele
Vasile, Enrico
Cascinu, Stefano
Zagonel, Vittorina
Zaniboni, Alberto
Melisi, Davide
Milella, Michele
Febbraro, Antonio
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
[32] A Phase II Study of Nab-Paclitaxel (Nab-P) in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR Mutations
Baik, Christina
Goulart, Bernardo
Nguyen, Katherine
Lee, Sylvia
Eaton, Keith
Chow, Laura
Rodriguez, Cristina
Santana-Davila, Rafael
Wood, Rebecca
Martins, Renato
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1227 - S1227
[33] Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine (nab-P/G) vs FOLFIRINOX (FFX) in patients (pts) with advanced pancreatic cancer (aPC)
Chiorean, E. G.
Cheung, W. Y.
Giordano, G.
Kim, G.
Al-Batran, S-E.
ANNALS OF ONCOLOGY, 2018, 29 : 245 - 246
[34] Analysis of activity, efficacy and safety of first line Nab Paclitaxel (Nab-P) and Gemcitabine (G) in advanced pancreatic cancer (APDAC) frail and elderly patients (pts)
Giordano, G.
De Vita, F.
Melisi, D.
Vaccaro, V.
Zaniboni, A.
Zagonel, V.
Vasile, E.
Passardi, A.
Leo, L.
Ventriglia, J.
Marciano, R.
Russano, M.
Conca, R.
Andreozzi, F.
Lucchini, E.
Musettini, G.
Bertocchi, P.
Bergamo, F.
Milella, M.
Febbraro, A.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S445 - S445
[35] Neoadjuvant atezolizumab (atezo) and nab-paclitaxel (nab-p) in patients (pts) with triple-negative breast cancer (TNBC) with suboptimal clinical response to doxorubicin and cyclophosphamide (AC).
Yam, Clinton
Mittendorf, Elizabeth A.
Sun, Ryan
Huo, Lei
Damodaran, Senthil
Rauch, Gaiane M.
Candelaria, Rosalind P.
Adrada, Beatriz E.
Seth, Sahil
Symmans, William Fraser
Murthy, Rashmi Krishna
White, Jason B.
Ravenberg, Elizabeth
Clayborn, Alyson
Prabhakaran, Sabitha
Valero, Vicente
Thompson, Alastair Mark
Tripathy, Debu
Moulder, Stacy L.
Litton, Jennifer Keating
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[36] A phase I study of two different schedules of nab-paclitaxel (nab-P) with ascending doses of vandetanib (V) with expansion in patients (Pts) with pancreatic cancer (PC).
El-Khoueiry, A. B.
Iqbal, S.
Lenz, H.
Gitlitz, B. J.
Yang, D.
Cole, S.
Duddalwar, V.
Garcia, A.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[37] SPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: A phase I/II study
Von Hoff, D. D.
Ramanathan, R.
Borad, M.
Laheru, D.
Smith, L.
Wood, T.
Korn, R.
Desai, N.
Iglesias, J.
Hidalgo, M.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[38] Metronomic chemotherapy (mCHT) in HER2-ve advanced breast cancer (ABC) patients (pts): What has changed over the time? Preliminary results of the VICTOR-6 study.
Cazzaniga, Marina Elena
Casadei, Virginia
Cagossi, Katia
Cavanna, Luigi
Cursano, Maria Concetta
De Conciliis, Enrico Maria Romano
Gebbia, Vittorio
Melegari, Elisabetta
Pellegrino, Benedetta
Pinotti, Graziella
Rossello, Rosalba
Russo, Salvatore
Ortu, Salvatore
Saracchini, Silvana
Stocchi, Lucia
Toniolo, Davide
Scognamiglio, Giovanni
Valerio, Maria Rosaria
Vandone, Anna Maria
Clivio, Luca
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[39] Real-world comparative effectiveness analysis of second-line (2L) nab-paclitaxel (nab-P) vs paclitaxel (Pac) in patients (Pts) with metastatic breast cancer (MBC)
Pelletier, C.
Parisi, M.
Gluck, S.
Ni, Q.
Braiteh, F.
ANNALS OF ONCOLOGY, 2016, 27
[40] Nivolumab (nivo) plus nab-paclitaxel (nab-P) plus carboplatin (C) in patients (pts) with non-small cell lung cancer (NSCLC): Interim results from a multicenter phase I study.
Waterhouse, David Michael
Goldman, Jonathan Wade
George, Ben
O'Dwyer, Peter J.
Ye, Moncy
Chen, Tianlei
Trunova, Nataliya
Kelly, Karen
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

← 1 2 3 4 5 →